Ono Pharmaceutical Co., Ltd. (FRA:ON4)

Market Cap	6.74B +43.2%
Revenue (ttm)	2.77B +4.5%
Net Income	338.99M -15.7%
EPS	0.72 -15.6%
Shares Out	n/a
PE Ratio	19.88
Forward PE	n/a
Dividend	0.47 (3.49%)
Ex-Dividend Date	Sep 29, 2025

Volume	n/a
Average Volume	45
Open	13.90
Previous Close	13.70
Day's Range	13.60 - 13.90
52-Week Range	8.95 - 14.20
Beta	n/a
RSI	63.00
Earnings Date	Feb 2, 2026

About Ono Pharmaceutical

Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules for malignant tumors; and ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabet...

• Industry: Pharmaceutical Preparations
• Founded: 1717
• Employees: 4,287
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: ON4

Financial Performance

In fiscal year 2025, Ono Pharmaceutical's revenue was 486.87 billion, a decrease of -3.14% compared to the previous year's 502.67 billion. Earnings were 50.05 billion, a decrease of -60.89%.

Financial numbers in JPY